A curated, growing network of laboratory partners.
DMC is building and coordinating a curated network of specialty laboratory, scientific, reimbursement, and commercialization partners that can be assembled around the requirements of a specific diagnostic program.
One relationship. Coordinated capability.
The network model is designed to simplify access to specialized diagnostic capability — across molecular oncology, infectious disease, toxicology, women's health, and anatomic pathology — through coordinated relationships and centralized strategic accountability, rather than requiring a client to source and manage each capability independently.
Partners are engaged program by program. DMC coordinates the relationships; each laboratory remains responsible for its own accreditation, licensure, and clinical operations.
Enterprise, specialty, and diverse-owned partners.
Enterprise laboratories
Reference and hospital-affiliated laboratories offering broad menu coverage.
Specialty laboratories
Focused, high-complexity labs in molecular, genomics, pathology, and toxicology.
Diverse-owned laboratories
A developing consortium of minority-, woman-, and LGBTQIA+-owned CLIA laboratories — coordinated by DMC, itself a woman- and LGBTQIA+-owned firm — relevant to supplier diversity and enterprise contracting objectives.
Coordinated capability under senior accountability.
- 01
Simplified contracting
A coordinated commercial structure and a single point of strategic accountability, rather than managing each laboratory relationship separately. - 02
Specialty depth
Access to sub-specialty pathology, molecular, and reference testing without building it in-house. - 03
Supplier diversity
A deliberate pathway to engage minority-, woman-, and LGBTQIA+-owned laboratory partners, coordinated by a woman- and LGBTQIA+-owned firm. - 04
Quality expectations
Partners are selected against accreditation, quality, and turnaround expectations defined per program and reviewed by DMC.